Management of endometrial cancer

Women's Health

Volumn 4, Issue 5, 2008, Pages 479-489

  Fowler, Wiley ^a   Mutch, David ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Endometrial cancer; Hormonal therapy; Risk factors; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PROGESTERONE; TAMOXIFEN; TAXANE DERIVATIVE;

ABDOMINAL HYSTERECTOMY; ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CURETTAGE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; FEMALE; GENETIC ASSOCIATION; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; MENOPAUSE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NULLIPARA; OBESITY; PATHOGENESIS; PATIENT MONITORING; PREOPERATIVE EVALUATION; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY; UNSPECIFIED SIDE EFFECT; VAGINA DISCHARGE;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; WOMEN'S HEALTH;

EID: 53749083495     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.4.5.479     Document Type: Review

References (67)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15(1), 10-17 (1983).
3. Hale GE, Hughes CL, Cline JM: Endometrial cancer: hormonal risk factors, the perimenopausal "window of risk," and isoflavones. J. Clin. Eidocrinol. Metab. 87(l), 3-15 (2002).
4. Purdie DM, Green AC: Epidemiology of endometrial cancer. Best Pract. Res. Clin. Obstet. Gynecol. 15(3), 341-354 (2001).
5. Tropé CG, Alektiar KM, Sabbatini PJ, Zaino RJ: Corpus: epithelial tumors. In: Principles and Practice of Gynecologic Oncology (4th Edition). Hoskins WJ, Young RC, Markman M, Perez CA, Barakat R, Randall M (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 823-872, (2005).
6. Fisher B, Costantino JP, Redmond CK et al.: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl Cancer Inst. 86(7), 527-537 (1994).
7. Fisher B, Costantino, JR Wickerham DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90(18), 1371-1388 (1998).
8. ACOG Committee Opinion No. 336: Tamoxifen and uterine cancer. American College of Obstetrics and Gyncology. Obstet. Gynecol. 107(6), 1475-1478 (2006).
9. Aarnio M, Mecklin JP, Aaltonen LA et al.: Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int. J. Cancer 64(6), 430-433 (1995).
10. Aarnio M, Sankila R, Pukkala E et al.: Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int. J. Cancer 81(2). 214-218 (1999).
11. Guillem JG, Wood WC, Moley JF et al.: ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J. Clin. Oncol. 24(28), 4642-4660 (2006).
12. Taylor N, Mutch DM: Gynecologic manifestations of hereditary nonpolyposis colorectal cancer: from inherited to sporadic disease. Oncology 20(1), 85-94 (2006).
13. Offit K, Kohut K, Clagett B et al.: Cancer genetic testing and assisted reproduction. J. Clin. Oncol. 24(29), 4775-4782 (2006).
14. Part VIII. Gynecologic sites, 29. Corpus uteri. In: AJCC Cancer Staging Handbook (6th Edition). Green FL, Fritz AG, Balch CM et al. (Eds). Springer-Verlag, NY, USA (2002).
15. Korman RJ, Kaminski PF, Norris HJ: The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer 56(2), 403-412 (1985).
16. Trimble CL, Kauderer J, Zaino R et al.: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4), 812-819 (2006).
17. Mutter GL, Lin MC, Fitzgerald JT et al.: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl Cancer Inst. 92(11), 924-930 (2000).
18. Iax SF, Kendall B, Tashiro, H, Slebos RJS, Ellensco LH: The frequency of p53. K-Ras mutations, and microsateffite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88(4), 814-824 (2000).
19. Mutter GL, Baak JP, Fitzgerald JT et al.: Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol. Oncol. 83(2), 177-185 (2001).
20. Risinger JI, Maxwell GI, Chandrampuli BVR et al.: Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 63(1), 6-11 (2003).
21. Santin AD: HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? Gynecol. Oncol. 88(3), 263-265 (2003).
22. ACOG Committee on Practice Bulletins - Gynecology, American College of Obstetricians and Gynecologists: ACOG practice bulletin: management of anovulatory bleeding. Int. J Gynaecol. 0bstet. 72(3), 263-271 (2001).
23. Bradley WH, Boente MP, Brooker D et al.: Hysteroscopy and cytology in endometrial cancer. Obstet. Gynecol. 104(5), 1030-1033 (2004).
24. Goldstein RB, Bree RL, Benson CB et al.: Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Consensus Conference statement. J. Ultrasound. Med. 20(10), 1025-1036 (2001).
25. Karlsson B, Granberg S, Wikland M et al.: Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: a Nordic multicenter study. Am. J. Obstet. Gynecol. 172(5), 1488-1494 (1995).
26. Getpook C, Wattanakumtornkul S: Endometrial thickness screening in premenopausal women with abnormal uterine bleeding. J. Obstet. Gynaecol. Res. 32(6). 588-592 (2006).
27. Tabor A, Watt HC, Wald NJ: Endometrial thickness as a test for endometrial cancer in women with postmenopausal bleeding. Obstet. Gynecol. 99(4), 663-670 (2002).
28. Hsieh CH, ChangChien CC, Lin H et al.: Can a preoperative CA 125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol. Oncol. 86(1), 28-33 (2002).
29. Fung-Kee-Fung M, Dodge J, Elit L et al.: Follow-up after primary therapy for endometrial cancer: a systematic review Gynecol. Oncol. 101(3), 520-529 (2006).
30. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR: Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed. Pharmacother. 58(1), 24-38 (2004).
31. Akin O, Mironov S. Pandit-Taskar N, Hann LE: Imaging of uterine cancer. Radiol. Clin. North Am. 45(1), 167-182 (2007).
32. Creasman WT, Odicino F, Maisonneuve P et al.: Carcinoma of the corpus uteri in the 26th annual report on the results of treatment in gynecologic cancer. Pecorelli S, (Ed.). Int. J Gynecol. Obstet. 95(Suppl. 1), S105-S143 (2006).
33. Hirai Y, Takeshima N, Kato T, Haumi K: Malignant potential of positive peritoneal cytology in endometrial cancer. Obstet. Gynecol. 97(5), 725-728 (2001).
34. Mariani A, Webb MJ, Keeney GL et al.: Endometrial cancer: predictors of peritoneal failure. Gynecol. Oncol. 89(2), 236-242 (2003).
35. Kadar N, Homesley HD, Malfetano JH: Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol. Oncol. 46(2), 145-149 (1992).
36. Zaino R, Whitney C, Brady MF et al.: Simultaneously detected endometrial and ovarian carcinomas - a clinicopathologic study of 74 cases: a Gynecologic Oncology Group study. Gynecol. Oncol. 83(2), 355-362 (2001).
37. Soliman PT, Slomovitz BM, Broaddus RR et al.: Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol. Oncol. 94(2), 456-462 (2004).
38. Malur S, Possaver M, Michels W, Schneider A: Laparoscopic-assisted vaginal versus abdominal surgery in patients with endometrial cancer - a prospective randomized trial. Gynecol. Oncol. 80(2), 239-244 (2001).
39. Tozzi, R, Malur S, Koehler C, Schneider A: Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J. Minim. Invasive Gynecol. 12(2), 130-136 (2005).
40. Spirtos NM, Eisenkop SM, Boike G, Schlaerth JB, Cappellari JO: Laparoscopic staging in patients with incompletely staged cancers of the uterus, ovary, fallopian tube, and primary peritoneum: a Gynecologic Oncology Group (GOG) study. Am. J. Obstet. Gynecol., 193(5), 1645-1649 (2005).
41. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB: Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study. Cancer 60(S8), 2035-2041 (1987).
42. Mariani A, Keeney GL, Aletti G, Webb MJ, Haddock MG, Podratz KC: Endometrial carcinoma: paraaortic dissemination. Gynecol. Oncol. 92(3), 833-838 (2004).
43. Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J: Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. Obstet. Gynecol. 95(4), 553-556 (2000).
44. Eltabbakh GH: Intraoperative clinical evaluation of lymph nodes in women with gynecologic cancer. Am. J. Obstet. Gynecol. 184(6), 1177-1181 (2001).
45. Yabushita H, Shimazu M, Yamada H et al.: Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol. Oncol. 80(2), 139-144 (2001).
46. Kilgore L, Partridge EE, Alvarez RD et al.: Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 56(1), 29-33 (1995).
47. Morrow CP, Bundy BN, Kurman RJ et al.: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group stud Gynecol. Oncol. 40(1), 55-65 (1991).
48. Aadlers J, Abeler V, Kolstad et al.: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 56(4), 419-427 (1980).
49. Creutzberg CL, van Putten WLJ, Koper PC et al.: Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355(9213), 1404-1411 (2000).
50. Nout RA, Putter H, Jürgenliemk-Schulz IM et al.: Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial. J. Clin. Oncol. 26, (Abstract LBA5503) (2008).
51. Keys HM, Roberts JA, Brunetto VL et al.: A Phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 92(3), 744-751 (2004).
52. Jolly S, Vargas C, Kumar T et al.: Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol. Oncol. 97(3), 887-892 (2005).
53. Alektiar KM, Venkatraman E, Chi DS, Barakat RR. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 62(1), 111-117 (2005).
54. Rose PG, Cha SD, Tak WK et al.: Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 24(2), 229-233 (1992).
55. Randall ME, Filiaci VL, Muss H et al.: Randomized Phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin, chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 24(1), 36-44 (2006).
56. Fleming GF, Brunetto VL, Gella D et al.: Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22(11), 2159-2166 (2004).
57. Low JS. Wong EH, Tan HS et al.: Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol. Oncol. 97(1), 171-177 (2005).
58. Steed H. Manchul L, Rosen B et al.: Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy. Int. J. Gynecol. Cancer 16(Suppl. 1), 278-285 (2006).
59. Horton J, Begg CB. Arseneault J, Bruckner H, Creeth R, Hahn RG: Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat. Rep. 62(1), 159-161 (1978).
60. Aapro MS, van Wijk FH, Bolis G et al.: Doxorubicin versus doxorubicin and cisplatin in endometrial carcinorm: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann. Oncol. 14(3), 441-448 (2003).
61. Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C: A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 12(7), 1408-1414 (1994).
62. Calero F, Asins-Codoner E, Jimeno J et al.: Epirubicin in advanced endometrial carcinoma: a Phase II study of the Grupo Ginecologic Espanol para el Tratamiento Oncologico (GGETO). Eur. J. Cancer 27(7), 864-866 (1991).
63. Thigpen IT, Blessing JA, Hornesley H, Creasman WT, Sutton G: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol. Oncol. 33(1), 68-70 (1989).
64. Burke TW, Munkarah A, Kavanagh JJ et al.: Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol. Oncol. 51(3), 397-400 (1993).
65. Lincoln S, Blessing JA, Lee RB, Rocereto TF: Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gyncecologic Ontology Group study. Gynecol. Oncol. 88(3), 277-281 (2003).
66. Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ: Intrauterine progesterone treatment of early endometrial cancer. Am. J. Obstet. Gynecol. 186(4), 651-657 (2002).
67. Ramirez PT, Frumovitz M, Bdurka DC, Sun CC, Levenback C: Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol. Oncol. 95(1), 133-138 (2004).